The short answer
Calcium supplements may increase high-calcium risk with indapamide. Review your total calcium and vitamin D intake with the prescriber; a few hours of separation is not an established solution.
What this answer covers
Oral calcium supplements with indapamide. Calcium salts differ in elemental calcium content; dietary calcium and combination calcium-vitamin D products are distinct exposures.
- Supplement or preparation
- Calcium
- Medication ingredient
- indapamide
Why calcium supplements need review
Indapamide can reduce calcium loss in urine. Its UK prescribing information specifically warns that calcium salts can increase high-calcium risk through this mechanism. This is a reason to review supplementation, especially with a history of high calcium or a parathyroid disorder.
High calcium is not inevitable
An 11-person indapamide study found lower urinary calcium without a serum calcium change. The U.S. label reports only slight average serum increases in its trials. A newer low-dose study excluded calcium and vitamin D supplement users, so its reassuring results cannot establish safety of that combination.
Review total intake and blood tests
Give the prescriber the elemental calcium amount and any vitamin D in each product. A reported case involved calcium-vitamin D, indapamide and omeprazole, with suspected underlying hyperparathyroidism. Your clinical history and tests matter more than assuming everyone needs to stop calcium.
Spacing does not address kidney retention
Taking calcium a few hours apart has not been shown to prevent this kidney-related effect. Ask whether the dose or monitoring should change, and do not stop prescribed bone treatment on your own. Persistent nausea, weakness or confusion warrants medical assessment.
Evidence and practical considerations
Side effects & toxicity
Calcium supplements may increase high-calcium risk with indapamide because urinary calcium elimination can fall; individual assessment is appropriate.
- Exact scope
- Oral calcium supplements with indapamide. Calcium salts differ in elemental calcium content; dietary calcium and combination calcium-vitamin D products are distinct exposures. with Exact indapamide RxCUI 5764 IN, confirmed by current NLM properties. Oral indapamide dose and release formulation are retained; evidence for hydrochlorothiazide, other diuretics or combination antihypertensive products is not automatically equivalent.
- Medication form and route
- Oral
What remains uncertain
- Current SmPC specifically warns about calcium salts. Exact studies show reduced urinary calcium without universal high serum calcium; the co-use case is confounded. No safe universal supplement dose or spacing fix established.
Factors that may matter: Dose and duration; Exact supplement preparation; Kidney function; Other medicines; Baseline electrolyte status.
Read the supporting source summaries
Source 1: Current U.S. prescribing information
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral indapamide 1.25 or 2.5 mg tablets; additional dose-ranging study data.
Recommends periodic electrolyte and renal-function assessment. Potassium reductions were dose-related; some low measurements normalized without intervention. Calcium increases in indapamide studies were only slight. Includes a thiazide-like magnesium-loss warning.
How this applies: Exact medication guidance with explicit dose and nutrient distinctions. Exact indapamide RxCUI 5764 IN, confirmed by current NLM properties. Oral indapamide dose and release formulation are retained; evidence for hydrochlorothiazide, other diuretics or combination antihypertensive products is not automatically equivalent.
A label class warning is not proof that every patient has magnesium depletion or that routine supplements are required. Higher-dose risks and other diuretics cannot be assigned to every low-dose regimen.
Source 2: Current prescribing information
medicines.org.uk · Source check Sep 10, 2026
Population: Patients prescribed oral indapamide 2.5 mg.
Calcium salts may increase hypercalcemia risk through reduced urinary calcium elimination. Stimulant laxatives add to hypokalemia risk; non-stimulant laxatives are advised. Low potassium increases arrhythmia risk, particularly with long QT or digitalis, and may cause muscle injury. Low magnesium can make low potassium refractory.
How this applies: Exact indapamide guidance supports conditional calcium/laxative and electrolyte-management conclusions.
Regulatory guidance, not direct clinical trials for every botanical. Does not establish universal supplement requirements, a fixed supplement dose or protective spacing.
Source 3: Original clinical research
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 11 patients with essential hypertension.
Urinary calcium fell without a serum calcium change; moderate hypokalemia occurred.
How this applies: Exact drug renal handling, not proof that supplements always cause high calcium.
Small study with no calcium-supplement intervention. Original fullTextXML request failed; abstract-only.
Source 4: Original clinical research
ebi.ac.uk · Source check Sep 10, 2026
Population: 101 adults with idiopathic hypercalciuria, randomized to indapamide or hydrochlorothiazide; 83 completed 18 months.
Indapamide reduced urinary calcium. Mean magnesium, sodium and potassium remained within normal ranges; the severe hypokalemia event occurred in the hydrochlorothiazide arm.
How this applies: Exact low-dose indapamide counterweight to universal electrolyte-depletion claims, with population and comparator boundaries.
Open-label selected kidney-stone population, attrition and group-average outcomes. Excluded calcium and vitamin D supplementation, so cannot establish safety of co-use. No fracture-prevention conclusion.
Source 5: Original conference case abstract
endocrine-abstracts.org · Source check Sep 10, 2026
Population: One 68-year-old woman taking indapamide, calcium-vitamin D supplements and omeprazole.
High calcium and very low magnesium improved after all three treatments were stopped and magnesium was replaced. Authors suspected underlying mild hyperparathyroidism unmasked by indapamide and calcium.
How this applies: Exact indapamide co-exposure with a calcium-vitamin D combination; constituent effects cannot be separated.
Conference abstract, multiple simultaneous interventions and other contributors. Does not isolate vitamin D or establish a universal risk, safe dose or spacing interval.
Source 6: Authoritative medication terminology
rxnav.nlm.nih.gov · Source check Sep 10, 2026
Population: Medication terminology.
Identifies indapamide as IN.
How this applies: Exact medication identifier.
Does not establish formulation equivalence or a clinical interaction.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Sources checked and article drafted. | |
| Research summary published |
Article revision: 51551c1162ab99de
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.